Farxiga granted Priority Review in the US for the treatment of patients with chronic kidney disease
6 January 2021 07:00 GMT Farxiga granted Priority Review in the USfor the treatment of patients with chronic kidney disease Farxiga could become the first SGLT2 inhibitor approved to treatpatients with chronic kidney disease, with and without type-2 diabetes AstraZeneca's Farxiga (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The Food and Drug Administration (FDA) grants Priority Review to regulatory submissions for medicines that offer significant